107 related articles for article (PubMed ID: 32990738)
1. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy.
Pinnix CC; Gunther JR; Fang P; Bankston ME; Milgrom SA; Boyce D; Lee HJ; Nair R; Steiner R; Strati P; Ahmed S; Iyer SP; Westin J; Parmar S; Rodriguez MA; Nastoupil L; Neelapu S; Flowers C; Dabaja BS
JAMA Netw Open; 2020 Sep; 3(9):e2013935. PubMed ID: 32990738
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study.
Chugh S; Panda G; Mokal S; Jain H; Bagal B; Khanna N; Epari S; Punatar S; Nayak L; Gokarn A; Khattry N; Sengar M; Laskar S; Goda JS
Indian J Med Res; 2024 Feb; 159(2):193-205. PubMed ID: 38577858
[TBL] [Abstract][Full Text] [Related]
3. Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.
Rosenbrock J; Kaul H; Oertel M; Celik E; Linde P; Fan J; Eichenauer DA; Bröckelmann PJ; von Tresckow B; Kobe C; Dietlein M; Fuchs M; Borchmann P; Eich HT; Baues C
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38631539
[TBL] [Abstract][Full Text] [Related]
4. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M; Jacob AS; Kaul H; Kobe C; Kuhnert G; Pabst T; Greil R; Bröckelmann PJ; Topp MS; Just M; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Dührsen U; Meissner J; Viardot A; Eich HT; Baues C; Diehl V; Rosenwald A; Buehnen I; von Tresckow B; Dietlein M; Borchmann P; Engert A; Eichenauer DA
Leukemia; 2024 Jan; 38(1):160-167. PubMed ID: 37845285
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapy.
Yahalom J
Curr Hematol Malig Rep; 2014 Sep; 9(3):212-6. PubMed ID: 24939521
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin Lymphoma in Adults.
Bröckelmann PJ; Eichenauer DA; Jakob T; Follmann M; Engert A; Skoetz N
Dtsch Arztebl Int; 2018 Aug; 115(31-32):535-540. PubMed ID: 30149835
[TBL] [Abstract][Full Text] [Related]
7. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K
Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902
[TBL] [Abstract][Full Text] [Related]
8. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
Lo AC; Liu A; Liu Q; Yasui Y; Castellino SM; Kelly KM; Hererra AF; Friedberg JW; Friedman DL; Schwartz CL; Pei Q; Kessel S; Bergeron-Gravel S; Dama H; Roberts K; Constine LS; Hodgson DC
JAMA Netw Open; 2024 Jan; 7(1):e2351062. PubMed ID: 38241048
[TBL] [Abstract][Full Text] [Related]
9. Breast Hypoplasia and Decreased Lactation From Radiation Therapy in Survivors of Pediatric Malignancy: A PENTEC Comprehensive Review.
Lo AC; Ronckers C; Aznar MC; Avanzo M; van Dijk I; Kremer LCM; Gagliardi G; Howell RM; Rancati T; Constine LS; Marcus KJ
Int J Radiat Oncol Biol Phys; 2024 Jun; 119(2):549-559. PubMed ID: 34627655
[TBL] [Abstract][Full Text] [Related]
10. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.
Meyer RM; Hoppe RT
Blood; 2012 Nov; 120(23):4488-95. PubMed ID: 22821764
[TBL] [Abstract][Full Text] [Related]
11. Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects.
Gilbert ES; Curtis RE; Hauptmann M; Kleinerman RA; Lynch CF; Stovall M; Smith SA; Weathers R; Andersson M; Dores GM; Fraumeni JF; Fossa SD; Hall P; Hodgson DC; Holowaty EJ; Joensuu H; Johannesen TB; Langmark F; Kaijser M; Pukkala E; Rajaraman P; Storm HH; Vaalavirta L; van den Belt-Dusebout AW; Aleman BM; Travis LB; Morton LM; van Leeuwen FE
Radiat Res; 2017 Feb; 187(2):186-195. PubMed ID: 28118119
[TBL] [Abstract][Full Text] [Related]
12. Current concepts and controversies in the management of early stage Hodgkin lymphoma.
Maeda LS; Lee M; Advani RH
Leuk Lymphoma; 2011 Jun; 52(6):962-71. PubMed ID: 21463118
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy for Advanced Hodgkin Lymphoma with Initial Bulk: A Combined Analysis of Two Randomized Trials.
Hughes RT; Razavian NB; Shenker RF; Kelsey CR; Smith S; D'Agostino RB; Winkfield KM
Adv Radiat Oncol; 2024 May; 9(5):101450. PubMed ID: 38550369
[TBL] [Abstract][Full Text] [Related]
14. Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma.
Yılmaz U; Zulfaliyeva G; Güzelli AN; Özmen D; Elverdi T; Salihoğlu A; Eskazan AE; Öngören Ş; Başlar Z; Ar MC
J Chemother; 2023 Nov; ():1-8. PubMed ID: 37974409
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.
Ali S; Basit A; Kazmi AS; Sidhu A; Badar F; Hameed A
Pak J Med Sci; 2016; 32(6):1408-1413. PubMed ID: 28083035
[TBL] [Abstract][Full Text] [Related]
16. Effect of organ size and position on out-of-field dose distributions during radiation therapy.
Scarboro SB; Stovall M; White A; Smith SA; Yaldo D; Kry SF; Howell RM
Phys Med Biol; 2010 Dec; 55(23):7025-36. PubMed ID: 21076195
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Early Stages Hodgkin Lymphoma During Pregnancy.
Avilés A; Nambo MJ; Neri N
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018006. PubMed ID: 29326803
[TBL] [Abstract][Full Text] [Related]
18. Impact of Modern Low Dose Involved Site Radiation Therapy on Normal Tissue Toxicity in Cervicothoracic Non-Hodgkin Lymphomas: A Biophysical Study.
Roers J; Rolf D; Baehr A; Pöttgen C; Stickan-Verfürth M; Siats J; Hering DA; Moustakis C; Grohmann M; Oertel M; Haverkamp U; Stuschke M; Timmermann B; Eich HT; Reinartz G
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136257
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before.
Saddi J; Barcellini A; Gotti M; Mazzacane A; Tolva A; Lazic T; Arcaini L; Zecca M; Orlandi E; Filippi AR
Hematol Oncol; 2024 May; 42(3):e3269. PubMed ID: 38650534
[TBL] [Abstract][Full Text] [Related]
20. Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma-A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group.
Oertel M; Hölscher P; Hering D; Kittel C; Fuchs M; Haverkamp U; Borchmann P; Eich HT
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
